Latus Bio announced today clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application for LTS-101, a gene therapy candidate that’s intended to treat the CNS manifestations of CLN2 disease. The FDA has also granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations for LTS-101. 

We made early progress! As of this morning, we were nearing $300 on the way to our $2,000 goal. Stay tuned for more updates on our social media channels!